Australia Develops Better Way to Measure Diabetes Treatment Satisfaction

A study from Australia has introduced and validated a promising new tool for measuring how people with Type 1 diabetes truly feel about managing their condition — and it could change how American patients and their doctors evaluate treatment success beyond just blood sugar numbers.

What the Researchers Did

Scientists at Deakin University in Victoria, Australia tested a 22-question survey called the Diabetes Management Experiences Questionnaire (DME-Q). Unlike traditional tools that focus solely on blood glucose outcomes, the DME-Q captures the lived experience of diabetes management across three important dimensions: Convenience, Effectiveness, and Intrusiveness.

The questionnaire was tested on 149 adults with Type 1 diabetes, with an average age of 44 years. Participants had been living with diabetes for an average of 24 years, and 52% were women. Their average HbA1c was 7.8% (equivalent to an estimated average blood glucose of approximately 178 mg/dL). The study compared people using hybrid closed-loop (HCL) insulin systems — sometimes called artificial pancreas technology — against those on standard therapy over 26 weeks.

What They Found

The DME-Q proved to be a reliable, well-structured measurement tool. Key findings included:

• Strong internal consistency across all three subscales (reliability scores ranging from 0.74 to 0.84), meaning the questionnaire consistently measures what it intends to measure.
• Meaningful correlations with established measures of diabetes distress and treatment satisfaction, confirming the questionnaire captures real psychological experiences.
• Patients using hybrid closed-loop technology scored significantly higher on both Effectiveness and Total Satisfaction compared to those on standard therapy — validating the tool's ability to detect meaningful differences between treatments.

Why the International Perspective Matters

Australia has long been a leader in diabetes technology research and patient-centered care measurement. Their healthcare system's emphasis on quality-of-life outcomes alongside clinical metrics offers American researchers and clinicians a valuable model. The DME-Q was adapted from an already-validated glucose monitoring questionnaire, giving it a strong scientific foundation that translates well across English-speaking countries, including the United States.

Why This Matters for US Patients

In the United States, diabetes care is most commonly evaluated through HbA1c targets. The American Diabetes Association (ADA) currently recommends an HbA1c below 7.0% (estimated average glucose of 154 mg/dL) for most non-pregnant adults. However, achieving that number tells only part of the story. Many patients struggle with the daily burden of monitoring, injections, alarms, and lifestyle restrictions — factors that powerfully affect long-term adherence and mental health.

The DME-Q offers US clinicians and researchers a validated, practical way to measure these burdens systematically. As more Americans adopt advanced technologies like hybrid closed-loop insulin systems — now covered by many US insurance plans — having a reliable satisfaction tool becomes especially important for FDA evaluations, insurance coverage decisions, and clinical trial design.

For patients, this research is a reminder that how you feel about your diabetes management is a legitimate and measurable health outcome — not just a footnote to your lab results.

Citation

Hendrieckx C, Husin M, Russell-Green S, et al. The diabetes management experiences questionnaire: Psychometric validation among adults with type 1 diabetes. Diabetic Medicine: A Journal of the British Diabetic Association. 2024. DOI: 10.1111/dme.15195. PMID: 37562414.